All News

pill,pain,med,hand

Pain Management in Rheumatoid Arthritis

Jack Cush, MD

BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.

Read Article
RheumNow Podcast square

Participation is Up! (1.31.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. We also have two call-in cases on "Ask Cush Anything".

Be sure to join in the fun at RNL 2025 next weekend - Gong Show Karaoke; what will you sing?

Read Article
Hepatitis B (Keep)

AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals

Jack Cush, MD

The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.

Read Article
exercise.workout.jpg

Young Males and Future Risk of MSK and Chronic Diseases

Jack Cush, MD

A large cohort of 18-year-old Swedish males were followed longitudinally for cardiovascular, respiratory, and musculoskeletal outcomes.

Read Article
celebrex.jpg

Celecoxib Lowers Colon Cancer Recurrence Risk

Jack Cush, MD

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib

Read Article
Lifestyle diet alcohol risk obesity

Proinflammatory Diet Increases Gout Risk

MedPage Today

Some dietary habits are worse than others when it comes to gout risk for women, a large study indicated.

Read Article
uveitis eye iritis

Adalimumab Withdrawal in Uveitis Patients

Jack Cush, MD

Adalimumab is an effective treatment for JIA-associated uveitis and has been FDA approved for such use - but for how long and can the drug be withdrawn? An adalimumab (ADA) withdrawal trial has shown recurrence of uveitis, arthritis, or both, when the disease was previously controlled on ADA.

Read Article
Gout pills injection

Do Rheumatologists Follow 2020 ACR Guidelines on Gout?

Jack Cush, MD

Schlessinger and colleagues report that US Rheumatologists generally adhere to and agree with the 2020 American College of Rheumatology (ACR) Guideline for the Management of Gout, although knowledge gaps and practice variance exists.

Read Article
Celecoxib Lowers Colon Cancer Recurrence Risk The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to… https://t.co/tIoMtRlwKt https://t.co/fzOAplwJLi
Dr. John Cush RheumNow ( View Tweet)
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
Dr. John Cush RheumNow ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Dr. John Cush RheumNow ( View Tweet)
ACR Applauds Second Round of Medicare Drug Price Negotiations The ACR applauded the announcement of additional drugs subject to pricing negotiations with the CMS. This second round includes nintedanib (Ofev) and apremilast (Otezla), which are used to treat common and rare… https://t.co/z1LkpWMXqg https://t.co/hqjkqTqJxw
Dr. John Cush RheumNow ( View Tweet)
SubAnalysis of STOP Gout Trial: 277 pts w/ CKD received either allopurinol or febuxostat. Most achieved SUA goal (79% vs 81%), fewer allopurinol pts had gout flares (32% vs 45%; P=0.02); AKI only seen stage w/ 3 CKD (allopurinol > febuxostat) https://t.co/wwfVCei4Ej https://t.co/W8Y7KxcSd4

Links:

Dr. John Cush RheumNow ( View Tweet)
Open label trial of starting MTX in 11 uncontrolled gout pts previously Rx w/ IV pegloticase (PEG 2-27x) showed if gout pts failed PEG monotherapy, only 1/11 (9%) showed a good response to adding MTX w/ PEG. MTX must be started w/ PEG initiation to work https://t.co/aoBtyIRbQe https://t.co/RNe03O6Z1N

Links:

Dr. John Cush RheumNow ( View Tweet)
Febuxostat (ULORIC) is discontinued by the manufacturer in the USA. This week an FDA update on drug shortages list announced Uloric has been discontinued. Takeda sited dropping sales, generic competition, and CV safety concerns in the last decade. GENERIC febuxostat should still… https://t.co/QcUNCUFfvJ https://t.co/oBdwkcN177
Dr. John Cush RheumNow ( View Tweet)
post hoc analysis of 4 registration trials of pegloticase, show rates of MACE and Thromboembolic Events were Infrequent (<1.5%; 35.4 events/1000 PY), similar to general gout population (31.7 events/1000 person-years) https://t.co/v6ZqtL4yB2 https://t.co/NA0j20Oew2

Links:

Dr. John Cush RheumNow ( View Tweet)
Systematic review of 14 studies using administrative/med. records data on >130 million people & 1 million dementia cases, finds the risk of Alzheimers/Dementia reduced w/ Antimicrobials, vaccines & NSAID antiinflammatories (but incr w/ DM drugs, vitamins, antipsychotics)… https://t.co/p79s5Pw4k2 https://t.co/9DO1WO2NuG
Dr. John Cush RheumNow ( View Tweet)
ACR: Congress Fails to Reform PBMs, Mitigate Medicare Cuts Save The ACR praised the limited extension of Medicare telehealth coverage but criticized Congress for not passing measures to increase transparency in PBM practices, address insurer issues, or prevent upcoming Medicare… https://t.co/pJ5f6LvELe https://t.co/jT3UJAx5It
Dr. John Cush RheumNow ( View Tweet)
Medicare has announced another 15 expensive drugs (now total 25) undergoing price negotiation with manufacturers. Enbrel and Stelara were in the 1st ten. Included in the next 15 Rx are Ofev (nintenib) & Otezla (apremilast) & GLP-1 drugs. https://t.co/SBwSprvo6K… https://t.co/okJXJCgOFm https://t.co/im2ggtgvt3

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has sent a Drug Safety Letter to VETERINARIANS about the use of Librela (bedinvetmab) & reported adverse reactions, deaths and neurological problems (ataxia, seizures, paresis). Rx was approved 5/23 to treat pain from osteoarthritis in dogs. https://t.co/LIZ4ZzXtmk https://t.co/uOVc2xsD5g

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×